Navigation Links
Therapeutic Pipeline of Portal Hypertension Reviewed for 2015 in New Market Research Report
Date:11/11/2015

PUNE, India, November 11, 2015 /PRNewswire/ --

New market research titled "Portal Hypertension - Pipeline Review, H2 2015" overviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities.

This report provides comprehensive information on the therapeutic development for Portal Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Portal Hypertension and special features on late-stage and discontinued projects. Complete report on H2 2015 pipeline review of Portal Hypertension with 20 market data tables and 13 figures, spread across 69 pages is available at http://www.reportsnreports.com/reports/432838-portal-hypertension-pipeline-review-h2-2015.html .

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Company Profiles discussed in this report includes Conatus Pharmaceuticals Inc., Galectin Therapeutics, Inc., Gilead Sciences, Inc., Intercept Pharmaceuticals, Inc., Mezzion Pharma Co. Ltd. and Ono Pharmaceutical Co., .Ltd. Drugs Profiles discussed in this report includes emricasan, GR-MD-02, obeticholic acid, ONO-1266, Px-102 and udenafil.

Scope of the report: The report provides a snapshot of the global therapeutic landscape of Portal Hypertension and reviews key players involved in the therapeutics development for Portal Hypertension and enlists all their major and minor projects summarizing all the dormant and discontinued pipeline projects. A review of the Portal Hypertension products under development by companies and universities/research institutes based on information derived from company and industry-specific sources, pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages, detailed assessment of monotherapy and combination therapy pipeline projects, coverage of the Portal Hypertension pipeline on the basis of target, MoA, route of administration and molecule type and latest news and deals relating related to pipeline products. Order a copy of this report @ http://www.reportsnreports.com/purchase.aspx?name=432838 .

Featured News & Press Releases: Sep 23, 2015: Conatus Announces Top-line Results From Multicenter Phase 2 Portal Hypertension Clinical Trial in Patients With Liver Cirrhosis. Nov 10, 2014: Conatus Pharmaceuticals Presents Late-Breaking Poster At AASLD Annual Meeting. Oct 08, 2014: Conatus Pharmaceuticals Announces Acceptance Of Late-Breaking Abstract For AASLD Annual Meeting. Sep 02, 2014: Conatus Pharmaceuticals Initiates Phase 2 Trial in Patients with Liver Cirrhosis and Separate Open Label Phase 2 Trial in Cirrhosis Patients with Portal Hypertension. Nov 08, 2012: Intercept Pharma To Present Phase IIa Portal Hypertension Data At AASLD''s Annual Liver Meeting.

List of Tables 

Number of Products under Development for Portal Hypertension, H2 2015
Number of Products under Development for Portal Hypertension - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Portal Hypertension Therapeutics - Recent Pipeline Updates, H2 2015
Portal Hypertension - Dormant Projects, H2 2015
Portal Hypertension - Discontinued Products, H2 2015

More reports on pharmaceuticals market are available at http://www.reportsnreports.com/market-research/pharmaceuticals/ .

About Us: 

ReportsnReports.com is an online market research reports library of 500,000+ in-depth studies of over 5000 micro markets. Not limited to any one industry, ReportsnReports.com offers research studies on agriculture, energy and power, chemicals, environment, medical devices, healthcare, food and beverages, water, advanced materials and much more.

Contact:
Ritesh Tiwari
UNIT no 802, Tower no. 7, SEZ
Magarpatta city, Hadapsar
Pune - 411013
Maharashtra, India.
+ 1-888-391-5441
sales@reportsandreports.com

Connect With Us on:
Facebook: https://www.facebook.com/pages/ReportsnReports/191441427571689
LinkedIn: http://www.linkedin.com/company/reportsnreports
Twitter: https: //twitter.com/marketsreports
G+ / Google Plus: https://plus.google.com/111656568937629536321/posts
Pinterest: http://www.pinterest.com/comeonseo/reportsnreports/
RSS/Feeds:  http: //http://www.reportsnreports.com/feed/l-latestreports.xml



'/>"/>
SOURCE ReportsnReports
Copyright©2015 PR Newswire.
All rights reserved


Related medicine technology :

1. Tobira Therapeutics Reports Third Quarter 2015 Financial Results
2. WuXi PharmaTech and Lilly Announce Strategic Collaboration to Develop Novel Therapeutic in China
3. Astellas to Acquire Ocata Therapeutics
4. PTC Therapeutics Reports Third Quarter 2015 Financial Results, Provides Corporate Update and Reviews Key Findings from ACT DMD
5. UChicago and Evelo Therapeutics Partner to Advance Microbiome-based Cancer Immunotherapy
6. Therabron Therapeutics Receives Accelerated Second Tranche from Series B Financing and Expands Investor Syndicate
7. Cachexia Pipeline Review and Therapeutic Development for H2 2015 Available in Market Research Report
8. Clinical Data Featuring Trovagenes Precision Cancer Monitoring Platform to be Presented at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
9. Mirati Therapeutics Reports Third Quarter 2015 Financial Results And Provides Business Update
10. Global Market Study on Next-Generation Antibody Therapeutics: Biosimilar Antibody Products to Witness Highest Growth by 2022 - Reportlinker Review
11. Nektar Therapeutics Reports Financial Results for the Third Quarter of 2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/6/2017)... , Sept. 6, 2017  Robert G. Szewc, M.D., ... Professional Member in recognition of his contributions to the ... as a Nephrologist at the practice of Kidney and ... kidney care and hypertension solutions. He has worked in ... of career experience, as well as expertise in kidneys, ...
(Date:9/6/2017)... -- NeuroRx, a clinical stage biopharma company developing the first ... been granted Fast Track status by the US Food and ... followed by NRX-101 (D-cycloserine + lurasidone). The company will shortly ... therapy targeting patients who are admitted to Emergency Departments with ... ...
(Date:9/5/2017)... 2017  Xyntek Inc. has announced another milestone in their continued growth and ... meet the growing demands of customer engagements regionally.  ... Xyntek's new Midwest office is located at 318 West Adams Street, Suite 1528, ... Xyntek's recently ... ...
Breaking Medicine Technology:
(Date:9/25/2017)... ... September 25, 2017 , ... ... announced its latest release of SentinelSecure™, version 3.0, will be available in a ... This newest version of SentinelSecure™ comes with several new enhancements including support for ...
(Date:9/25/2017)... ... September 25, 2017 , ... FDAnews Expert Insight Series:, Device ... p.m. – 3:00 p.m. ET, http://www.fdanews.com/deviceregulation      , FDA Commissioner ... four short months:, ,     The first device recall over cybersecurity ...
(Date:9/25/2017)... (PRWEB) , ... September 25, 2017 , ... The award ... in helping those with disabilities. Each year the award is given to those who ... with disabilities live their best lives in communities of their choosing. Recent recipients of ...
(Date:9/25/2017)... ... September 25, 2017 , ... Just ask anyone old enough to remember what ... headgear so wired up and containing so much metal that jokes about radio reception ... its treatments can barely be observed. As a result, it’s now a billion-dollar industry ...
(Date:9/25/2017)... Lancaster, California (PRWEB) , ... September 25, 2017 ... ... like to announce the launch of its new website. No need to ... WDD has the answer. Go to welldonedesigns.com where all orders are printed and ...
Breaking Medicine News(10 mins):